PHASE II STUDY OF COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER REFRACTORY TO IRINOTECAN, OXALIPLATIN, AND FLUOROPYRIMIDINES

被引：0
|
作者：
Yuki, S. [1 ]
Shitara, K. [2 ]
Yoshida, M. [3 ]
Takahari, D. [2 ]
Utsunomiya, S. [4 ]
Yokota, T. [2 ]
Sato, Y. [2 ]
Tajika, M. [2 ]
Muro, K. [2 ]
机构：
[1] Hokkaido Univ Hosp, Sapporo, Hokkaido 060, Japan
[2] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan
[3] Osaka Med Coll, Takatsuki, Osaka 569, Japan
[4] Nagoya Kyouritsu Hosp, Nagoya, Aichi, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：216 / 216
页数：1
相关论文
共 50 条
  • [41] A phase II study of panitumumab plus irinotecan for metastatic colorectal cancer with wild KRAS, resistant to fluoropyrimidine, oxaliplatin, and irinotecan in Japanese (OGSG1001).
    Taira, Koichi
    Yoshida, Motoki
    Sugimoto, Naotoshi
    Kii, Takayuki
    Kuwakado, Shin
    Fukunaga, Mutsumi
    Hasegawa, Hiroko
    Kato, Takeshi
    Miyake, Yasuhiro
    Hata, Taishi
    Tokunaga, Yukihiko
    Takeda, Koji
    Daga, Haruko
    Yoshinami, Tetsuhiro
    Shimokawa, Toshio
    Sakai, Daisuke
    Kurokawa, Yukinori
    Satoh, Taroh
    Tsujinaka, Toshimasa
    Furukawa, Hiroshi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [42] Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer
    Zekri, Jamal
    Baghdadi, Mohammed Abbas
    Ibrahim, Refaei Belal
    Meliti, Abdelrazak
    Sobahy, Turki M.
    ECANCERMEDICALSCIENCE, 2022, 16 : 1 - 16
  • [43] Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population
    Chen, Ye
    Cao, Dan
    Bi, Feng
    Li, Qiu
    Qiu, Meng
    MEDICAL ONCOLOGY, 2014, 31 (05)
  • [44] Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population
    Ye Chen
    Dan Cao
    Feng Bi
    Qiu Li
    Meng Qiu
    Medical Oncology, 2014, 31
  • [45] A Phase II Study of High-Dose Cetuximab plus Irinotecan in Colorectal Cancer Patients with KRAS Wild-Type Tumors Who Progressed after Standard Dose of Cetuximab plus Irinotecan
    Fora, Ahmad A.
    McMahon, Jeanne A.
    Wilding, Greg
    Groman, Adrienne
    Ma, Wen Wee
    Romano, Karen S.
    Fakih, Marwan G.
    ONCOLOGY, 2013, 84 (04) : 210 - 213
  • [46] A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab
    Naoki Takahashi
    Satoru Iwasa
    Masaru Fukahori
    Kazuki Sudo
    Yusuke Sasaki
    Hirokazu Shoji
    Yoshitaka Honma
    Natsuko Tsuda Okita
    Atsuo Takashima
    Tetsuya Hamaguchi
    Narikazu Boku
    Yasuhiro Shimada
    Kazufumi Honda
    Tesshi Yamada
    Yasuhide Yamada
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 567 - 575
  • [47] A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab
    Takahashi, Naoki
    Iwasa, Satoru
    Fukahori, Masaru
    Sudo, Kazuki
    Sasaki, Yusuke
    Shoji, Hirokazu
    Honma, Yoshitaka
    Okita, Natsuko Tsuda
    Takashima, Atsuo
    Hamaguchi, Tetsuya
    Boku, Narikazu
    Shimada, Yasuhiro
    Honda, Kazufumi
    Yamada, Tesshi
    Yamada, Yasuhide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 567 - 575
  • [48] Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
    Braghiroli, Maria Ignez Freitas Melro
    Filho, Daniel Santos Rocha Sobral
    Fagundes, Juliana Goes Martins
    Mendoza, Elizabeth Zambrano
    Neffa, Maria Fernanda Batistuzzo Vicentini
    Campos, Karla Souza
    da Fonseca, Leonardo Gomes
    Bonadio, Renata Colombo
    Talans, Aley
    Braghiroli, Oddone Freitas Melro
    Mathias-Machado, Maria Cecilia
    Sabbaga, Jorge
    Venchiarutti, Camila Motta
    Hoff, Paulo Marcelo Gehm
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 42
  • [49] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    Cunningham, D
    Humblet, Y
    Siena, S
    Khayat, D
    Bleiberg, H
    Santoro, A
    Bets, D
    Mueser, M
    Harstrick, A
    Verslype, C
    Chau, I
    Van Cutsem, E
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04): : 337 - 345
  • [50] Initial report of a phase I/II study of S-1 and irinotecan (IRIS) in combination with cetuximab in patients with wild-type RAS metastatic colorectal cancer
    Oki, E.
    Samura, H.
    Okumura, H.
    Ohchi, T.
    Orita, H.
    Kobayashi, K.
    Kinjo, T.
    Mori, S.
    Touyama, T.
    Ohgaki, K.
    Kawanaka, H.
    Makiyama, A.
    Ureshino, N.
    Kotaka, M.
    Shimose, T.
    Saeki, H.
    Nishimaki, T.
    Baba, H.
    Maehara, Y.
    ANNALS OF ONCOLOGY, 2018, 29 : 166 - 166
12345